First Time Loading...

Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 171.07 USD -2.4% Market Closed
Updated: Jul 18, 2024
Have any thoughts about
Abbvie Inc?
Write Note

Intrinsic Value

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. [ Read More ]

The intrinsic value of one ABBV stock under the Base Case scenario is 147.08 USD. Compared to the current market price of 171.07 USD, Abbvie Inc is Overvalued by 14%.

Key Points:
ABBV Intrinsic Value
Base Case
147.08 USD
Overvaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Abbvie Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ABBV stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

AbbVie delivers strong Q1 performance and raises 2024 guidance
Earnings Call Summary

AbbVie delivers strong Q1 performance and raises 2024 guidance

AbbVie reported impressive Q1 results, with adjusted earnings per share of $2.31, beating guidance by $0.16. Total net revenues reached $12.3 billion, driven by over 15% growth in their X HUMIRA platform. Outstanding performance in drugs like SKYRIZI and RINVOQ led to revenue increases of $200 million and $100 million, respectively. The company raised its full-year EPS guidance to between $11.13 and $11.33, and total net revenues to about $55 billion. Despite challenges from the cost of recent acquisitions and foreign exchange impacts, AbbVie's diversified portfolio and strong pipeline position it well for continued growth.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abbvie Inc

Current Assets 38.9B
Cash & Short-Term Investments 18.1B
Receivables 11.9B
Other Current Assets 8.9B
Non-Current Assets 110B
Long-Term Investments 305m
PP&E 5B
Intangibles 95.7B
Other Non-Current Assets 9.1B
Current Liabilities 41.5B
Accounts Payable 31.3B
Short-Term Debt 3m
Other Current Liabilities 10.2B
Non-Current Liabilities 99.3B
Long-Term Debt 63.8B
Other Non-Current Liabilities 35.5B
Efficiency

Earnings Waterfall
Abbvie Inc

Revenue
54.4B USD
Cost of Revenue
-18.3B USD
Gross Profit
36.1B USD
Operating Expenses
-20.1B USD
Operating Income
16B USD
Other Expenses
-10B USD
Net Income
6B USD

Free Cash Flow Analysis
Abbvie Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
73/100
Profitability
Score

Abbvie Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
Positive Net Debt
38/100
Solvency
Score

Abbvie Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 187.77 USD with a low forecast of 171.7 USD and a high forecast of 217.35 USD.

Lowest
Price Target
171.7 USD
0% Upside
Average
Price Target
187.77 USD
10% Upside
Highest
Price Target
217.35 USD
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ABBV?

Click here to dive deeper.

Competitive Landscape

Ownership

ABBV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Price Appreciation

ABBV Price
Abbvie Inc

1M 1M
0%
6M 6M
+5%
1Y 1Y
+25%
3Y 3Y
+59%
5Y 5Y
+198%
10Y 10Y
+349%
Annual Price Range
171.07
52w Low
136.58
52w High
182.1
Price Metrics
Average Annual Return 29.14%
Standard Deviation of Annual Returns 5.51%
Max Drawdown -15%
Shares Statistics
Market Capitalization 307.7B USD
Shares Outstanding 1 765 869 952
Percentage of Shares Shorted 0.92%

ABBV Return Decomposition
Main factors of price return

What is price return decomposition?

ABBV News

Other Videos

Last Important Events
Abbvie Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Abbvie Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Abbvie Inc Logo
Abbvie Inc

Country

United States of America

Industry

Biotechnology

Market Cap

307.7B USD

Dividend Yield

3.58%

Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Contact

ILLINOIS
North Chicago
1 N Waukegan Rd
+18479327900.0
https://www.abbvie.com/

IPO

2013-01-02

Employees

50 000

Officers

Chairman & CEO
Mr. Richard A. Gonzalez
President & COO
Mr. Robert A. Michael
Executive VP & CFO
Mr. Scott T. Reents
Executive VP & COO
Dr. Azita Saleki-Gerhardt Ph.D.
Executive VP & Chief Commercial Officer
Mr. Jeffrey Ryan Stewart
Senior VP & Chief Scientific Officer of Global Research
Dr. Thomas J. Hudson M.D.
Show More
Senior Vice President of Investor Relations
Ms. Elizabeth Shea
Executive VP, General Counsel & Secretary
Mr. Perry C. Siatis
Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Sanjay Narayan
Executive VP & Chief Human Resources Officer
Mr. Timothy J. Richmond
Show Less

See Also

Discover More
What is the Intrinsic Value of one ABBV stock?

The intrinsic value of one ABBV stock under the Base Case scenario is 147.08 USD.

Is ABBV stock undervalued or overvalued?

Compared to the current market price of 171.07 USD, Abbvie Inc is Overvalued by 14%.